Journal of Peking University (Health Sciences) ›› 2024, Vol. 56 ›› Issue (1): 51-56. doi: 10.19723/j.issn.1671-167X.2024.01.009

Previous Articles     Next Articles

Application of double-layer soft tissue suture closure technique in the surgical treatment of patients with mandible medication-related osteonecrosis of the jaw of early and medium stages

Ying ZHOU,Ning ZHAO,Hongyuan HUANG,Qingxiang LI,Chuanbin GUO,Yuxing GUO*()   

  1. Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices & Beijing Key Laboratory of Digital Stomatology & NHC Research Center of Engineering and Technology for Computerized Dentistry & NMPA Key Laboratory for Dental Materials, Beijing 100081, China
  • Received:2023-10-08 Online:2024-02-18 Published:2024-02-06
  • Contact: Yuxing GUO E-mail:gladiater1984@163.com
  • Supported by:
    the National Clinical Key Discipline Construction Project(PKUSSNKP-202114);China Postdoctoral Science Foundation(2022M720289);Chinese Stomatological Association Clinical Research Fund(CSA-SIS2022-0);Beijing Municipal Natural Science Foundation(7212137);the National Stomatology Center Suitable Technology Promotion Project(2023NCSHTP03)

RICH HTML

  

Abstract:

Objective: To investigate the clinical application effect of double-layer soft tissue (DLST) suture closure technique in patients with mandible medication-related osteonecrosis of the jaw (MRONJ) of early and medium stages resulted in application of anti-bone-resorptive drugs. Methods: Early to medium stage mandible MRONJ patients who underwent surgical treatment in the fourth ward of Peking University School and Hospital of Stomatology from October 2021 to September 2022 were included. Clinical information of the patients were collected, including primary disease, concomitant disease, medication regimen (drug type, duration of medication), MRONJ stage, clinical symptoms, imaging manifestations, etc. During surgery, after using marginal mandibulae resection to remove the necrotic bone, the wound was closed using DLST closure technique. Regular post-operative follow-up was performed to evaluate the therapeutic effect and complications of the DLST technique, the pain score and functional status of the patiens were evaluated. Results: This study totally included 13 patients, 12 women and 1 man, aged (66.69±13.14) years. Seven patients had osteoporosis, 2 had lung cancer, 3 had breast cancer and 1 had prostate cancer among their primary diseases; 7 had no concomitant diseases, 2 had diabetes mellitus, 2 had cardiovascular disease and 1 had dry syndrome. Intravenous zoledronic acid were used in 9 patients, the average duration was (37.7±20.0) months, and other drugs, such as letrozole tablets were taken in 7 patients at the same time; Denosumab injection was used in 3 patients for an average of (10.3±11.9) months; Alendronate sodium tablets were taken in 5 patients for an average of (55.20±27.20) months, and prednisone acetate tablets or acarbose tablets were taken to varying degrees in 2 patients. The average post-operative follow-up was 11.9 months (9 to 17 months), and all the 13 patients were cured without complications, such as pus overflow and so forth. The pre-operative score of Karnofsky performance status (KPS) in the patients was 68.46±14.05, and the post-operative score was 82.31±15.36, and the difference was statistically significant (P < 0.05). The pre-operative score of visual analogue scale (VAS) in the patients was 5.77±0.73 and the post-operative score was 0.38±0.51, and the difference had statistical significance (P < 0.001). Conclusion: The double-layer soft tissue suture closure technique can achieve good clinical results in patients with MRONJ of the mandible using anti-bone-resorptive drugs alone, and can provide clinical treatment ideas for MRONJ patients with more complicated drug use.

Key words: Medication-related osteonecrosis of the jaw, Double-layer soft tissue suture closure technique, Marginal mandibulectomy, Anti-bone-resorptive drugs, Surgical treatment

CLC Number: 

  • R782

Figure 1

Schematic of double-layer soft tissue suture closure design (mandible) A, osteonecrosis of mandible in stage Ⅱ; B, marginal mandibulectomy for the removement of the osteonecrosis; C, periosteum membrane cut off to increase the freeness of mucoperiosteal flap; D, the purpose of the first layer of suture is to reduce the tissue dead cavity and make the soft tissue as close to the remaining mandibular bone as possible; E, the purpose of the second layer of suture is to further allow the mucoperiosteal flaps of the cheek side and the lingual side close to increase the tightness."

Figure 2

Operative process of double-layer soft tissue suture closure A, MRONJ stage Ⅱ mandibular osteonecrosis; B, bucco-lingual mucoperiosteal flap was prepared after trimming the bone wound; C, the first layer of suture; D, the second layer of suture."

Table 1

Baseline data of patients"

Case Gender Age/years Primary disease Concomitant disease Chemotherapeutics Stage of MRONJ Clinical manifestation Imaging manifestation
Anti-bone resorption drugs/months Else
1 Female 63 Lung cancer - Zoledronic acid/26, denosumab/2 Crizotinib capsule 2 Soft tissue fistula Local thickening of bone
2 Male 71 Prostatic cancer - Zoledronic acid/31 Flutamide tablets, leuprorelin acetate, microspheres for injection 2 Soft tissue fistula Diffuse sclerosis of bone
3 Female 40 Breast cancer - Zoledronic acid/30, pamidronate/28 Palbociclib, fulvestrant, everolimus tablets 2 Soft tissue fistula Local thickening of bone
4 Female 64 Osteoporosis - Alendronate sodium/48, zoledronic acid/1 - 1 Soft tissue fistula Sequestration
5 Female 79 Osteoporosis - Zoledronic acid/60 - 1 Soft tissue fistula Sequestration,diffuse sclerosis of bone
6 Female 87 Osteoporosis Diabetes Alendronate sodium/103 Acarbose tablets 1 Soft tissue fistula Sequestration,diffuse sclerosis of bone
7 Female 85 Osteoporosis - Alendronate sodium/41 - 1 Soft tissue fistula Diffuse sclerosis of bone
8 Female 63 Lung cancer - Zoledronic acid/57 - 2 Soft tissue fistula Sequestration,diffuse sclerosis of bone
9 Female 63 Breast cancer Diabetes Zoledronic acid/64, denosumab/5 Trastuzumab, pertuzumab, paclitaxel, fulvestrant, capecitabine tablets 2 Soft tissue fistula Diffuse sclerosis of bone
10 Female 70 Osteoporosis Hypertension Zoledronic acid/40, alendronate sodium/48 - 1 Soft tissue fistula Sequestration
11 Female 74 Osteoporosis Coronary heart disease Denosumab/24 Leiflunomide tablets, tripterygium glycosides tablets, 1 Bone exposure Sequestration,diffuse sclerosis of bone
12 Female 52 Breast cancer - Zoledronic acid/30 Letrozole tablets, fulvestran, abemaciclib 2 Soft tissue fistula Uneven alveolar bone density
13 Female 56 Osteoporosis Sicca syndrome Alendronate sodium/36 Prednisone acetate tablets 1 Soft tissue fistula Sequestration,diffuse sclerosis of bone

Figure 3

Cases 4 (A) and 9 (B) 6-month post-operative wound healing of intra-oral soft tissue"

Figure 4

Panoramic radiograph of pre-operation (A) and 6-month post-operation (B) of case 6"

1 Marx RE . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61 (9): 1115- 1117.
doi: 10.1016/S0278-2391(03)00720-1
2 Ruggiero SL , Dodson TB . American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update[J]. J Oral Maxillofac Surg, 2014, 72 (10): 1938- 1956.
doi: 10.1016/j.joms.2014.04.031
3 郭玉兴, 王佃灿, 王洋, 等. 二膦酸盐药物治疗乳腺癌骨转移发生颌骨坏死的临床特点[J]. 北京大学学报(医学版), 2016, 48 (1): 80- 83.
doi: 10.3969/j.issn.1671-167X.2016.01.014
4 Ruggiero SL , Dodson TB , Aghaloo T , et al. American association of oral and maxillofacial surgeons' position paper on medication-related osteonecrosis of the jaws: 2022 update[J]. J Oral Maxillofac Surg, 2022, 80 (5): 920- 943.
doi: 10.1016/j.joms.2022.02.008
5 Yarom N , Shapiro CL , Peterson DE , et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline[J]. J Clin Oncol, 2019, 37 (25): 2270- 2290.
doi: 10.1200/JCO.19.01186
6 Carlson ER . Management of antiresorptive osteonecrosis of the jaws with primary surgical resection[J]. J Oral Maxillofac Surg, 2014, 72 (4): 655- 657.
doi: 10.1016/j.joms.2013.12.007
7 Abu-ld MH , Warnke PH , Gottschalk J , et al. "Bis-phossy jaws"-high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw[J]. J Craniomaxillofac Surg, 2008, 36 (2): 95- 103.
doi: 10.1016/j.jcms.2007.06.008
8 Wilde F , Heufelder M , Winter K , et al. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011, 111 (2): 153- 163.
doi: 10.1016/j.tripleo.2010.04.015
9 Hayashida S , Soutome S , Yanamoto S , et al. Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: A multicenter retrospective study with propensity score matching analysis[J]. J Bone Miner Res, 2017, 32 (10): 2022- 2029.
doi: 10.1002/jbmr.3191
10 Williamson RA . Surgical management of bisphosphonate induced osteonecrosis of the jaws[J]. Int J Oral Maxillofac Surg, 2010, 39 (3): 251- 255.
doi: 10.1016/j.ijom.2009.11.014
11 Lopes RN , Rabelo GD , Rocha AC , et al. Surgical therapy for bisphosphonate-related osteonecrosis of the jaw: Six-year experience of a single institution[J]. J Oral Maxillofac Surg, 2015, 73 (7): 1288- 1295.
doi: 10.1016/j.joms.2015.01.008
12 何悦, 陈珩, 安金刚, 等. 药物相关性颌骨坏死临床诊疗专家共识[J]. 中国口腔颌面外科杂志, 2023, 21 (4): 313- 325.
13 Altay MA , Radu A , Pack SE , et al. Medication-related osteonecrosis of the jaw: An institution' s experience[J]. Cranio, 2020, 38 (5): 333- 341.
doi: 10.1080/08869634.2018.1528711
14 安金刚, 吕晓鸣, 贾宽宽, 等. 下颌下腺转位在下颌骨3期药物相关性颌骨坏死手术中的应用[J]. 中华口腔医学杂志, 2021, 56 (5): 441- 446.
doi: 10.3760/cma.j.cn112144-20210203-00058
15 Caldroney S , Ghazali N , Dyalram D , et al. Surgical resection and vascularized bone reconstruction in advanced stage medication-related osteonecrosis of the jaw[J]. Int J Oral Maxillofac Surg, 2017, 46 (7): 871- 876.
doi: 10.1016/j.ijom.2017.01.023
16 Klingelhöffer C , Zeman F , Meier J , et al. Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws[J]. J Craniomaxillofac Surg, 2016, 44 (10): 1694- 1699.
doi: 10.1016/j.jcms.2016.08.001
17 Mücke T , Koerdt S , Jung M , et al. The role of mylohyoid flap in the treatment of bisphosphonate-related osteonecrosis of the jaws[J]. J Craniomaxillofac Surg, 2016, 44 (4): 369- 373.
doi: 10.1016/j.jcms.2015.12.017
18 Lemound J , Muecke T , Zeller AN , et al. Nasolabial flap improves healing in medication-related osteonecrosis of the jaw[J]. J Oral Maxillofac Surg, 2018, 76 (4): 877- 885.
doi: 10.1016/j.joms.2017.09.021
[1] Bin CHEN,Chao WU,Bin LIU,Tao YU,Zhen-yu WANG. Prognosis of patients with spinal intramedullary cavernous hemangioma by different treatments [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 652-657.
[2] Yu-xing GUO,Jian-yun ZHANG,Dian-can WANG,Chuan-bin GUO. Analysis of pathological characteristics of medication-related osteonecrosis of the jaw and discussion of clinical treatment strategies based on the pathological analysis results [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1190-1195.
[3] HONG Peng,TIAN Xiao-jun,ZHAO Xiao-yu,YANG Fei-long,LIU Zhuo,LU Min,ZHAO Lei,MA Lu-lin. Bilateral papillary renal cell carcinoma following kidney transplantation: A case report [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 811-813.
[4] Jie YANG,Ran ZHANG,Yu-nan LIU,Dian-can WANG. Plunging ranula presenting as a giant retroauricular mass: A case report [J]. Journal of Peking University(Health Sciences), 2020, 52(1): 193-195.
[5] Rong YANG,Qing-xiang LI,Chi MAO,Xin PENG,Yang WANG,Yu-xing GUO,Chuan-bin GUO. Multimodal image fusion technology for diagnosis and treatment of the skull base-infratemporal tumors [J]. Journal of Peking University(Health Sciences), 2019, 51(1): 53-58.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2007, 39(5): 507 -510 .
[2] . [J]. Journal of Peking University(Health Sciences), 2002, 34(1): 64 -67 .
[3] . [J]. Journal of Peking University(Health Sciences), 2001, 33(2): 181 -182 .
[4] . [J]. Journal of Peking University(Health Sciences), 2001, 33(5): 457 -461 .
[5] . [J]. Journal of Peking University(Health Sciences), 2002, 34(5): 599 -603 .
[6] . [J]. Journal of Peking University(Health Sciences), 2002, 34(6): 737 -738 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(6): 562 -564 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(6): 663 -665 .
[9] . [J]. Journal of Peking University(Health Sciences), 2008, 40(2): 146 -150 .
[10] . [J]. Journal of Peking University(Health Sciences), 2008, 40(4): 369 -373 .